Releases
If you would like to automatically receive our releases by e-mail, it takes just a moment to sign up for our subscription service.
Â
Latest releases from Lundbeck.
June 30, 2008
Headline results of Flurizan® in clinical phase III trial
Myriad Genetics, Inc. has today announced the outcome of a clinical phase III trial of Flurizan® (tarenflurbil) in 1,684 patients with mild Alzheimer's disease. The clinical phase III data do not correspond to the data observed in clinical phase II in patients with mild Alzheimer's disease. Lundbeck and Myriad will now investigate the data further to understand the outcome of the trial in which the compound did not meet the two primary endpoints.
Myriad Genetics, Inc. has today announced the outcome of a clinical phase III trial of Flurizan® (tarenflurbil) in 1,684 patients with mild Alzheimer's disease. The clinical phase III data do not correspond to the data observed in clinical phase II in patients with mild Alzheimer's disease. Lundbeck and Myriad will now investigate the data further to understand the outcome of the trial in which the compound did not meet the two primary endpoints.
June 16, 2008
Azilect® slows the progression of Parkinson's disease in clinical trial
Lundbeck's partner Teva Pharmaceutical Industries Ltd. has today announced the successful completion of ADAGIO, the phase III trial designed to demonstrate that Azilect® 1 mg tablets can slow down the progression of Parkinson's disease. In the trial, the currently marketed Azilect® 1 mg tablets met all three primary end points, as well as the secondary and additional end points, all with statistical significance. The study also confirmed the safety and tolerability of Azilect®.
Lundbeck's partner Teva Pharmaceutical Industries Ltd. has today announced the successful completion of ADAGIO, the phase III trial designed to demonstrate that Azilect® 1 mg tablets can slow down the progression of Parkinson's disease. In the trial, the currently marketed Azilect® 1 mg tablets met all three primary end points, as well as the secondary and additional end points, all with statistical significance. The study also confirmed the safety and tolerability of Azilect®.
May 30, 2008
Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities
H. Lundbeck A/S hereby reports transactions made by executives and persons and legal entities closely associated to them with shares in H. Lundbeck A/S and linked securities, cf. section 28a of the Danish Securities Trading Act.
H. Lundbeck A/S hereby reports transactions made by executives and persons and legal entities closely associated to them with shares in H. Lundbeck A/S and linked securities, cf. section 28a of the Danish Securities Trading Act.
May 26, 2008
Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities
H. Lundbeck A/S hereby reports transactions made by executives and persons and legal entities closely associated to them with shares in H. Lundbeck A/S and linked securities, cf. section 28a of the Danish Securities Trading Act.
H. Lundbeck A/S hereby reports transactions made by executives and persons and legal entities closely associated to them with shares in H. Lundbeck A/S and linked securities, cf. section 28a of the Danish Securities Trading Act.
May 23, 2008
Update on Share Buyback program in H. Lundbeck A/S
Lundbeck's Supervisory Board has acted on its authorization to acquire up to 10% of its shares. Under the program Lundbeck was to buy own shares for an amount of up to DKK 6 billion, cf. stock exchange announcement number 166 dated 17 August 2005.
Lundbeck's Supervisory Board has acted on its authorization to acquire up to 10% of its shares. Under the program Lundbeck was to buy own shares for an amount of up to DKK 6 billion, cf. stock exchange announcement number 166 dated 17 August 2005.
Go to top
H. Lundbeck A/S
Ottiliavej 9
DK-2500 Copenhagen Valby
Ottiliavej 9
DK-2500 Copenhagen Valby
Tel +45 36 30 13 11
Fax +45 36 30 19 40
Fax +45 36 30 19 40
The specialist in psychiatry and pioneer in neurology
Disclaimer & Privacy statement
Disclaimer & Privacy statement